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Philippe Clezardin in his original and complete review 
masterfully describes the bone metastasis process [1]. It 
seems to share many analogies with a famous fairy tale:
‘Once upon a time a very poor woodcutter lived in 
a tiny cottage in the forest with his two children, 
Hansel and Gretel. His second wife often ill-treated 
the children and was forever nagging the 
woodcutter. “Th   ere is not enough food in the house 
for us all. Th   ere are too many mouths to feed! 
We must get rid of the two brats, ” 
she declared’ [2].
Th  e determinants of ‘successful’ metastatic growth in a 
given organ (for example, bone marrow) are not com-
pletely understood, but there is a clear evidence to suggest 
that tumor cells and host tissue both play important roles 
in the metastatic process. Th  is model is based on 
experimental data evaluating cancer stem-like cells, a 
population of cells within a tumor mass able to leave the 
primary tumor mass and navigate through the blood-
stream to localize in new sites where the ‘soil’ can exert 
an important role on their fate [3,4]. For this reason, pre-
metastatic niches are thought to be fertile regions of 
tissue that facilitate the invasion, survival and/or 
prolifera  tion of metastatic tumor cells, providing a highly 
novel mechanism for the promotion of metastasis [5]. 
Moreover, chemokines are small chemo-attractant
cytokines that bind to speciﬁ  c G-protein-coupled trans-
membrane receptors present on the plasma membranes 
of target cells. Th  ese molecules can guide circulating 
cancer cells to the bone. So we can postulate that cross-
talk between the bone microenvironment and cancer 
cells can facilitate bone tropism of cancers cells.
‘On [Hansel and Gretel] walked and walked, till 
suddenly they came upon a strange cottage in the 
middle of a glade. “Th   is is chocolate!” gasped 
Hansel as he broke a lump of plaster from the wall. 
“And this is icing!” exclaimed Gretel, putting 
another piece of wall in her mouth. Starving but 
delighted, the children began to eat pieces of candy 
broken oﬀ   the cottage. “Isn’t this delicious?” said 
Gretel, with her mouth full. She had never tasted 
anything so nice. ’
We still do not know whether cancer cells already possess 
an osteomimetic phenotype when they detach from the 
primary tumor, or whether these characteristics are 
instead acquired when they colonize the bone niche. 
Th   ere is evidence that some cancer cells need a biological 
signature to invade bone [6]. Many molecules are 
produced from cancer cells invading the bone marrow. In 
addition to tumor cells invading the bone micro-
environment, they express several transcription factors, 
which are involved in acquisition of an osteomimetic 
phenotype. Th   is process of osteomimicry is essential for 
the anchorage and survival of cancer cells in the bone 
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© 2011 BioMed Central Ltdmicroenvironment. Targeting the bone metastatic process 
means targeting every step of the long path to the bone, 
beginning with the stem cell targets and the micro-
environment in the primary tumor via the chemo-
attractant chemokines released by the bone niche (bone 
marrow) and the corresponding cancer cell receptors, 
through to the osteomimicry phenomenon and the 
tumor-stroma interactions in the bone niche.
Cancer stem cells can be targeted during this acqui  si-
tion of self-renewal and migration ability (the epithelial-
mesenchymal transition process). In this respect, the 
most studied pathways are the WNT (Wingless-type), 
SHH (sonic hedgehog), NOTCH and PTEN (phosphatase 
and tensin homolog deleted on chromosome ten) 
pathways. In particular, the SHH pathway, highly 
expressed in cancer and mesenchymal stem cells, seems 
to be able to induce the bone modiﬁ  cations necessary to 
create the pre-metastatic niche [7]. Th   e most interesting 
bone chemo-attractant chemokine pathways for thera-
peutic targeting are the CXCR4 (C-X-C chemokine 
receptor type 4)/SDF-1 (stromal cell-derived factor-1) 
pathway, the RANK (receptor activator of nuclear factor 
kappa B)/RANKL (receptor activator of nuclear factor 
kappa B ligand) pathway, the bone morphogenetic 
protein (BMP)/BMP receptor axis, and the integrins 
system. For example, it has been demonstrated that 
activation of the CXCR4/SDF-1 pathway not only 
regulates migration and homing of cancer cells to the 
bone but also regulates the adhesion, invasion and 
induced cytoskeletal re  arrange  ment of cancer cells [8].
Finally, osteomimicry represents another potential 
thera  peutic target to prevent or reduce the tumor burden 
in the bone. Several phenotypic modiﬁ  cations have been 
demonstrated in cancer cells during their homing in the 
bone niche. One of the most interesting ‘osteomimicry 
processes’ involves the RANK/RANKL/osteoprotegerin 
pathway. In each bone mineral unit (BMU), RANKL is 
produced by osteoblasts and stromal cells where it 
induces osteoclast activation and increased bone resorp-
tion through interaction with RANK receptors expressed 
by osteoclast precursors. Osteoprotegerin represents the 
natural antagonist of RANKL. Th  e  RANK/RANKL 
pathway is involved in tumor-induced osteoclastogenesis 
and osteolysis. Moreover, it has recently been demon-
strated that many types of solid tumors express RANK 
both in primary sites and in metastatic bone [9]. Recent 
in vivo studies have demonstrated the association 
between RANK expression and cancer cell osteotropism. 
RANK is clearly associated with early bone metastasis 
formation in breast cancer [10]. Th  ese data allow us to 
consider this molecular pathway as one of the most 
exciting therapeutic targets for preventing and treating 
bone metastases.
Understanding fully this complexity represents a major 
challenge in anti-cancer research and a mandatory step 
towards the development of new drugs potentially able 
not only to reduce the consequences of metastatic bone 
lesions but also to target the pathogenic process from the 
‘bone preneoplastic niche’ to the ‘visceral preneoplastic 
niches’ and to target bone metastases.
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